Jade Biosciences, Inc. · NASDAQ:JBIO
Fairmount Funds Management LLC reported a 19.99% stake in Jade Biosciences, Inc. (Schedule 13D/A)
Event Jun 5, 2026 · Filed Jun 9, 2026
Fairmount Funds Management LLC reported a 19.99% stake in Jade Biosciences, Inc., 14,069,494 shares, with active intent on Jun 5, 2026. Filed Jun 9, 2026 (Schedule 13D/A).
- Stake
- 19.99%
- Shares
- 14,069,494
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 5 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Fairmount Funds Management LLC | 19.99% | 14,069,494 |
| Fairmount Healthcare Fund II L.P. | 16.22% | 11,413,677 |
| Fairmount Healthcare Co-Invest IV L.P. | 4.36% | 2,655,817 |
| Peter Evan Harwin | 19.99% | 14,069,494 |
| Tomas Kiselak | 19.99% | 14,063,511 |
Source
Related
- Jade Biosciences, Inc.
- Fairmount Funds Management LLC
- Jade Biosciences, Inc. shareholders
- Schedule 13D/A · Fairmount Funds Management LLC · Oct 8, 2025
- Schedule 13D · Fairmount Funds Management LLC · May 1, 2025
- Schedule 13G/A · Venrock Healthcare Capital Partners III, L.P. · Aug 14, 2026
- Schedule 13G/A · Bellevue Group AG · Aug 14, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Jul 17, 2026
- Schedule 13G/A · Janus Henderson Group PLC · Jul 8, 2026
- Schedule 13G/A · Janus Henderson Group PLC · May 15, 2026